Etravirine Production Cost Reports

The report provides a detailed analysis essential for establishing an Etravirine manufacturing plant. It encompasses all critical aspects necessary for Etravirine production, including the cost of Etravirine production, Etravirine plant cost, Etravirine production costs, and the overall Etravirine manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Etravirine production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Etravirine is an antiretroviral medicine used in the treatment of HIV-1 infection. It is used in combination with other antiretroviral agents in children and adults above two years of age with HIV diseases, who have previously experienced the HIV treatment. It is in the class of drugs popularly referred to as Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etravirine acts through the inhibition of DNA dependent and RNA dependent polymerase activities and does this by binding covalently to the active site of the reverse transcriptase enzyme of HIV-1.

The procurement of Etravirine is influenced by its utilization as an antiviral medication in the pharmaceutical and medical industries. The growing prevalence of HIV-1 infections is the main factor driving the demand for Etravirine. The rising frequency of drug-resistant strains of HIV highlights the value that Etravirine could present as a preferred treatment option. The use of this medicine as a part of combined therapy with other antiretroviral agents for improving control over oncogenic virus infection, makes it an advantageous choice in management according to healthcare providers.

In addition, increased patient compliance to antiretroviral treatments by creating awareness and access to health care services are supporting the growth of Etravirine market globally. The availability of its generic medications further fuels the growth in its market. Overall, industrial Etravirine procurement is influenced by its utilization in the pharmaceutical and medical industries, the rising cases of HIV-1 infections, the increasing prevalence of drug-resistant viral strains, the significance of the medication as a potential therapy choice, increasing healthcare awareness, accessibility to healthcare services, availability of the drug in generic versions, and regulatory approvals.

Raw Material for Etravirine Production

According to the Etravirine manufacturing plant project report, the key raw material used in the production of Etravirine includes 5-bromo-2,4,6-trichloropyrimidine.

Manufacturing Process of Etravirine

The extensive Etravirine production cost report consists of the following major industrial manufacturing process:

• Production from 5-bromo-2,4,6-trichloropyrimidine: The manufacturing process of Etravirine starts with the reaction of the starting compound with 4-aminobenzonitrile in refluxing dioxane to form an intermediate. The intermediate is treated with 4-hydroxy-3,5-dimethylbenzonitrile in N-methylpyrrolidone to give another intermediate. Finally, the intermediate undergoes an ammonification reaction with ammonia to produce Etravirine.

Etravirine, commercially known as Intelence, is a white to off-white crystalline solid having the molecular formula C20H15BrN6O and a molecular weight of 435.3 g/mol. It has an estimated water solubility of around 0.0169 mg/mL, indicating that it is lipophilic. It is readily soluble in glacial acetic acid, dissolves to some extent in methanol, very slightly soluble in water, and is almost insoluble in ethanol and other organic solvents. It has a log P value in the range of 3.67-5.54. The aminopyrimidine Etravirine is composed of 2,6-diaminopyrimidine with a 4-cyano-2,6-dimethylphenoxy substituent at position 4, a 4-cyanophenyl substituent linked to the 2-amino group, and a bromo substituent at position 5. It is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) used to treat HIV-1 infections.